The nurse reviews the client's test results. For each potential provider's prescription, click to specify if the potential prescription is anticipated or contraindicated for the client. There must be at least 1 selection in every row. There does not need to be a selection in every column.

• Ethambutol: Ethambutol is part of the standard initial four-drug regimen for active TB. It helps prevent the development of drug resistance while susceptibility results are pending and is routinely anticipated in treatment plans. • Isoniazid: Isoniazid is a first-line antitubercular medication used to inhibit mycolic acid synthesis in the bacterial cell wall. It is a core component of therapy for active TB and is expected unless contraindicated by liver toxicity. • Airborne precautions: TB is transmitted via airborne droplet nuclei, requiring airborne isolation to prevent spread. Negative-pressure rooms and appropriate respiratory protection are standard and anticipated nursing interventions. • Rifampin: Rifampin is another first-line medication that works by inhibiting bacterial RNA synthesis. It is essential for effective TB treatment and is routinely included in combination therapy. • Pyrazinamide: Pyrazinamide enhances the sterilizing effect of TB treatment during the intensive phase. It is anticipated in early treatment to shorten therapy duration and improve outcomes. • Monthly TB skin test for 1 year: Once active TB is confirmed, skin testing is no longer useful for monitoring treatment response. The TB skin test detects exposure, not disease activity or resolution, making it inappropriate in this context. • Contact precautions: TB does not spread through direct contact or contaminated surfaces. Airborne precautions are required instead, so contact precautions alone are insufficient and not indicated for TB management.